Pitavastatin: distinctive features in a new reality

Abstract

The treatment of atherosclerotic cardiovascular diseases (CVD) is actual worldwide and in Russia as the main reason of morbidity and mortality. The main reason of developing and progressing of CVD is dyslipidemia, in particular, high low density lipoprotein cholesterol (LDL-C). Management of dyslipidemia with statins is the main direction to low mortality rate from CVD. Pitavastatin is a statin with unique chemical structure and high affinity to HMG-CoA reductase molecule which result in more potent, than other statins efficacy against dyslipidemia. Pitavastatin has a reduced potential for drug–drug interactions and similar efficacy at the lowest dose. Pitavastatin is a statin of choice for management of dyslipidemia in comorbidity and elderly, in the presence of diabetes mellitus and metabolic disturbances, after kidney and heart transplantation and in patients with human immunodeficiency virus and COVID-19 (COronaVIrus Disease 2019), – in cases when use of other statins is limited or impossible.